PATTERNS OF CARE OF PATIENTS WITH AN OCCULT LOCOREGIONAL RELAPSE ON CHOLINE PET/CT AFTER A PRIOR CURATIVE TREATMENT FOR LOCALIZED PROSTATE CANCER Choline.

Slides:



Advertisements
Similar presentations
Università Campus Bio-Medico
Advertisements

Impact of cytokeratin-positive cells in bone marrow on survival in patients with non-metastatic prostate cancer treated by radiotherapy PURPOSE To evaluate.
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Contemporary practice of radiotherapy post radical prostatectomy at a tertiary referral centre in Australia Introduction  Adverse features on histopathology.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Management of locally advanced & metastatic prostate cancer Dr. Purvish. M. Parikh MD, DNB, PhD, FICP Professor & Head Department of Medical Oncology Tata.
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Imaging modalities in prostate cancer
Continuous versus Intermittent Androgen Deprivation Therapy for Prostate Cancer Robert Dreicer, M.D., M.S., FACP, FASCO Chair Dept of Solid Tumor Oncology.
Mechanism of Action Combidex in MR Imaging Mukesh Harisinghani, MD Department of Radiology, Massachusetts General Hospital.
Prostate Cancer Radical Prostatectomy
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
Steven Joniau Filip Ameye
M. Wirth Department of Urology, Technical University of Dresden Adjuvant or Salvage Radiotherapy after Radical Prostatectomy.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
 These slides were extracted from a larger set of comprising a presentation entitled “Comparing Treatment Results of PROSTATE CANCER” dated 15_01_2013(3).
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
PET after Chemotherapy in Rhabdomyosarcoma Connective Tissue Oncology Society November 19, 2005 Michelle L. Klem, Leonard H. Wexler, Ravinder Grewal, Heiko.
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
PSA Shared Care Jim Wood. Background A significant number of men with prostate cancer (CaP) are receiving regular hospital follow up (out- patient visits),
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Updated 5-year Biochemical Relapse-Free Survival after Prostate Brachytherapy Jenny P. Nobes St. Luke’s Cancer Centre, The Royal Surrey County Hospital,
Robert Dreicer, M.D., M.S., FACP Chair Dept of Solid Tumor Oncology
Lymphadenectomy in the surgical treatment of prostate cancer - does it influence survival? Oliver Hakenberg Urologische Klinik und Poliklinik Universitätsklinikum.
What’s new in PCA... Steven Joniau University Hospitals Leuven, Belgium EAU Guidelines 2010 update.
Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.
بسم الله الرحمن الرحيم ” قالوا سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم“
French Guidelines (SOR): Any Impact Since 1995? BN Bui Institut Bergonié, Bordeaux FSG CETOS 2005.
Combined Modality Treatment of Locally Advanced Prostate Cancer: Radiation Therapy (RT) with Concurrent Androgen Deprivation Therapy (ADT) Howard Sandler.
SC-PM6: Prediction Models in Medicine: Development, Evaluation and Implementation Michael W. Kattan, Ph.D. Ewout Steyerberg, Ph.D. Brian Wells, M.S., M.D.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
LOCAL TREATMENT OF OLIGOMETASTATIC DISEASE IN PROSTATE CANCER: LYMPHADENECTOMY Alberto Briganti, MD, fEBU Department of Urology Chair, Prostate Cancer.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Detected by 11 C-Choline PET/CT RJ Karnes MD, FACS Vice-Chair Associate Professor and.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Choline PET/CT Robert S. Bridwell MD MBA Founder and CMO Appian 360
Brain imaging prior to lung cancer resection
Using PET/CT in Prostate Cancer
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.
Using PET/CT in Prostate Cancer
Surgical Treatment in Locally Advanced Prostate Cancer
Prostate cancer นพ.ชัชชัย หอมเกตุ.
Is Brachytherapy 125I still needed in Prostate cancer treatment?
Radical Prostatectomy in pN+ Prostate Cancer
Compassionate People World Class Care
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
New Tracers for Prostate Cancer Imaging
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
RELAZIONE TRA “STAGE MIGRATION” E
Response to chemotherapy
Prof.S.M.Haider Faisal Hameed Wahab Kadri
Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Proportion of continuous, intermittent, and limited (
History: 71 yo male post radical prostatectomy 4 years ago for Gleason 4+5 prostate cancer Pre-op staging CT and MDP bone scan were negative for metastatic.
PSMA expression in pre- and posttreatment prostate carcinoma serum.
Presentation transcript:

PATTERNS OF CARE OF PATIENTS WITH AN OCCULT LOCOREGIONAL RELAPSE ON CHOLINE PET/CT AFTER A PRIOR CURATIVE TREATMENT FOR LOCALIZED PROSTATE CANCER Choline PET: Modification of strategy in  50% (Soyka D et al., EJNMMI 2012) Local, nodal and bone met staging compared to abdomino-pelvic staging alone w/ MR Lymphangiography (Ferumoxtran) or SN SPECT Sensitivity/Specificity:  90% for local failure 85-88% for nodal failure (Meta-analysis from Umbehr et al. Eur Urol 2013)

13 GETUG centers (Radiation Oncology Group) >400 patients with Choline PET for rising PSA 173 patients with LRF only  Patterns of LRF  Patterns of care Statistics: Descriptive only analyzes METHODS 50%≤T2a 81% ≤ GS7 78.4% N0 Median PSA 8.8 ng/mL [ ] 49% RP 34% PLND 61% EBRT 33% ADT 14% Prostate brachy

RESULTS Salvage therapy Distribution of failures Prostate 41% Prostate bed 11% SV 7.5% Nodes 60% ON 16.1% II 25.0% EI 42.0% CI 33.0% LA 25.9% IN 4.5% RP4.4% PLND10.5% Postop EBRT13.3% Nodal EBRT32.9% ADT alone5.2% Watchful waiting24.9%

PET-guided salvage therapy in a curative intent is rapidly growing (25% Watchful waiting and 5% ADT alone) Limits: retrospective, lack of follow-up, lack of pathology, Number of positive nodes may be underestimated Impact of PET-guided salvage therapy on BRFS, Regional- FS, Met-FS, CSS? Longer follow-up needed DISCUSSION